Regeneron's ZALTRAP a Surprise Hit in Phase III
By Catherine Shaffer
Thursday, April 28, 2011
Regeneron Pharmaceuticals Inc.'s (Nasdaq:RGEN) stock surged 28 percent on news that its Phase III VELOUR trial of Zaltrap (aflibercept) for metastatic colon cancer hit its primary endpoint of improving overall survival. Regeneron and partner Sanofi-Aventis will waste no time preparing marketing approval applications for the FDA and European Medicines Agency for submission in the second half of 2011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.